Events
We are happy to have been selected to participate in the German Accelerator program. The program’s target is to „empower German startup to scale globally“ – it goes without saying that this is 100% in line with Priavoid GmbH’s ambition. See you in Boston!
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.
